Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTP001 platform study in idiopathic pulmonary fibrosis
NL-OMON55928Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing LTP001 with Placebo (2 arms). Primary endpoint: Change from baseline to week 26 in forced vital capacity percent predicted. Started Oct 2023; status: recruiting.
02
Drugs
LTP001
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON55928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55928.